Peter Andersen

to-BBB Holding BV operated as a holding company with interest in providing central nervous system drug technology to the pharmaceutical and biotechnology industries. The firm developed medicines for the treatment of brain diseases. The company was headquartered in The Hague, the Netherlands.

BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands.

Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark.

Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona.

Part of ACADIA Pharmaceuticals, Inc., ACADIA Pharmaceuticals A/S utilizes technology to fuel drug discovery and clinical development. The private company is based in Glostrup, Denmark. The Danish company was founded by Peter Høngaard Andersen.

EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark.

Lundbeck Pharma A/S markets and sells medicines within Central Nervous System. It specializes in various illnesses and conditions such as depression, Schizophrenia, anxiety, alcohol dependence, and Parkinson's and Alzheimer's diseases. The company was founded on January 1, 1988 and is headquartered in Valby, Denmark.

Serendex Pharmaceuticals A/S engages in the research and development of pharmaceuticals for respiratory conditions. It develops drugs to treat respiratory conditions such as Pulmonary Alveolar Proteinosis, Bronchiectasis, Cystic Fibrosis related lung infections and Diffuse Alveolar Hemorrhage. The company was founded by Lars Heslet on October 31, 2008 and is headquartered in Horsholm, Denmark.

Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA.

Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland.

InnovationsFonden provides investment services. It invests in entrepreneurs, researchers, and businesses. The company was founded on January 4, 2005 and is headquartered in Copenhagen, Denmark.

Edvince AB engages in clinical research and development services. It operates as a biotech company that focuses on a new form of emergency treatment for stroke. The company was founded by Lars Ingvar Herbert Edvinsson in 2003 and is headquartered in Lund, Sweden.

Imara, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. The company was founded by James Gregg McArthur in 2016 and is headquartered in Brookline, MA.